Special Issue

20th Anniversary of Pharmaceuticals—Therapeutic Mechanisms of Nature Products against Insulin Resistance

Message from the Guest Editors

Insulin resistance corresponds to a reduced responsiveness of insulin-sensitive tissues to physiological levels of insulin. This disorder is present in several diseases, such as metabolic syndrome, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and cardiovascular diseases.

To improve metabolic disorders, pharmacological strategies include insulin sensitisers, insulin secretagogues, alphaglucosidase inhibitors, and sodium–glucose co-transporter 2 inhibitors. Natural products are also a source of active compounds that could be useful tools to improve metabolic disorders in combination with pharmacological drugs. They can originate from plants, animals, microorganisms, food ingredients, and traditional medicine, and can act directly on insulin resistance to improve glucose homeostasis. They can target insulin-sensitive tissues, such as skeletal muscle, adipose tissues, liver, or the cardiovascular system.

We thus invite investigators to provide studies investigating the therapeutic mechanisms of natural products at cellular and molecular levels on the target tissues that contribute to insulin resistance.

Guest Editors

Prof. Dr. Anne-Dominique Lajoix

Biocommunication in Cardio-Metabolism (BC2M), Faculty of Pharmacy, University of Montpellier, Montpellier, France

Dr. Didier Tousch

Qualisud, Faculty of Sciences, University of Montpellier, CIRAD, SupAgro, Montpellier, France

Deadline for manuscript submissions

closed (25 May 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/175501

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

